ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential "best-in-class" once-monthly subcutaneous amylin receptor agonist, as a clinical development candidate. ASCLETIS-B plans to submit an Investigational New Drug (IND) application to the U.S. FDA for ASC36 in the treatment of obesity in Q2 2026.

ASC36 is a peptide-based amylin receptor agonist developed by ASCLETIS, optimized for extended apparent half-life and higher bioavailability per milligram, enabling once-monthly subcutaneous dosing. Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B, stated that preclinical data suggest ASC36 could achieve best-in-class efficacy with monthly dosing, potentially offering superior weight loss benefits and a simpler, patient-friendly titration regimen.